In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
News|Articles|June 12, 2026
PLPS Launches MyClinicalSuite™ to Deliver Faster Clinical Trial Label Turnarounds Without Compromising Quality, Compliance, or Patient Safety
Listen
0:00 / 0:00
Key Takeaways
- Dedicated clinical-only production segregates trial work from commercial runs, minimizing queue conflicts and helping protect study milestones under compressed timelines.
- Accelerated labeling is positioned alongside patient safety and compliance requirements, using robust quality systems to reduce operational and regulatory risk.
Premium Label & Packaging Solutions launched MyClinicalSuite™, a clinical-dedicated label and packaging environment that segregates trial work from commercial production to accelerate timelines while maintaining regulatory compliance and data integrity.
Advertisement
Clinical trial sponsors face constant pressure to accelerate study timelines while maintaining strict regulatory compliance and data integrity. As trial designs become more complex and schedules continue to compress, even small delays in label production can impact critical study milestones.1
To help sponsors meet these challenges, Premium Label & Packaging Solutions (PLPS) has launched
Speed without compromise
Although quick turnarounds are important, clinical trial labels require more than just quick production. Every label must support patient safety, study integrity, and regulatory compliance. MyClinicalSuite™ was developed with the realities of today's trial protocols in mind. By combining advanced production capabilities, industry expertise, and robust quality systems, we’re able to provide accelerated timelines while reducing operational and regulatory risk.
Key advantages of MyClinicalSuite™
- Order size flexibility so that large or small batches are treated equally, regardless of size
- A responsive team of specialists to provide answers in real time
- Built-in accuracy and scheduling so late-stage changes can be executed flawlessly while adhering to timelines
- In-house variable data printing to support accurate patient control
- In-line vision inspection to ensure quality and secure clinical trial administration
The MyClinicalSuite™ portfolio offers a wide range of clinical trial labels and packaging applications, including booklets,
The launch of MyClinicalSuite™ further expands PLPS’s broader healthcare capabilities in pharmaceutical, medical device, OTC, and regulated healthcare markets across pressure sensitive labels, expanded content labels, shrink sleeves, flexible packaging, and specialty packaging applications.
Reference
- PLPS Launches MyClinicalSuite™ to Deliver Faster Clinical Trial Label Turnarounds Without Compromising Quality, Compliance, or Patient Safety. News release. PLPS. Accessed June 12, 2026.
https://premiumlabelandpackaging.com/myclinicalsuitelaunch/
Advertisement
Related to this article
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
4
Where AI Governance in Clinical Development Falls Short
5